Condition: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · High Grade B-Cell Lymphoma · Sponsor: National Cancer Institute (NCI)
This phase I trial studies the side effects and best dose of mosunetuzumab when given together with polatuzumab vedotin and lenalidomide in treating patients with diffuse large B-cell lymphoma (DLBCL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Mosunetuzumab and polatuzumab vedotin are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Polatuzumab, linked to a toxic agent called vedotin, attaches to CD79B positive cancer cells in a targeted way and delivers vedotin to kill them. Lenalidomide may stimulate or suppress the immune system in different ways and stop cancer cells from growing and by preventing the growth of new blood vessels that cancer cells need to grow. Giving mosunetuzumab with polatuzumab vedotin and lenalidomide may work better in treating patients with relapsed/refractory DLBCL.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| City of Hope Comprehensive Cancer Center | Duarte, California, United States | Recruiting |
| University of California Davis Comprehensive Cancer Center | Sacramento, California, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| Wake Forest University Health Sciences | Winston-Salem, North Carolina, United States | Recruiting |
| Case Western Reserve University | Cleveland, Ohio, United States | Recruiting |
| University of Oklahoma Health Sciences Center | Oklahoma City, Oklahoma, United States | Recruiting |
| University of Virginia Cancer Center | Charlottesville, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06015880